Evidence map›Paper›PMID 34853348›Full record

ArticleScientific reports2021

Communication pathways bridge local and global conformations in an IgG4 antibody.

Thomas Tarenzi, Marta Rigoli, Raffaello Potestio

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Fast, Accurate, and System-Specific Variable-Resolution Modeling of Proteins.Journal of chemical information and modeling · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Thomas Tarenzi *Department of Physics, University of Trento, Via Sommarive 14, 38123, Trento, Italy.
Marta Rigoli *Department of Physics, University of Trento, Via Sommarive 14, 38123, Trento, Italy.
Raffaello PotestioDepartment of Physics, University of Trento, Via Sommarive 14, 38123, Trento, Italy. raffaello.potestio@unitn.it.
University of Trento · ITIstituto Nazionale di Fisica Nucleare, Trento Institute for Fundamental Physics And Applications · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The affinity of an antibody for its antigen is primarily determined by the specific sequence and structural arrangement of the complementarity-determining regions (CDRs). Recent evidence, however, points toward a nontrivial relation between the CDR and distal sites: variations in the binding strengths have been observed upon mutating residues separated from the paratope by several nanometers, thus suggesting the existence of a communication network within antibodies, whose extension and relevance might be deeper than insofar expected. In this work, we test this hypothesis by means of molecular dynamics (MD) simulations of the IgG4 monoclonal antibody pembrolizumab, an approved drug that targets the programmed cell death protein 1 (PD-1). The molecule is simulated in both the apo and holo states, totalling 4 μs of MD trajectory. The analysis of these simulations shows that the bound antibody explores a restricted range of conformations with respect to the apo one, and that the global conformation of the molecule correlates with that of the CDR. These results support the hypothesis that pembrolizumab featues a multi-scale hierarchy of intertwined global and local conformational changes. The analysis pipeline developed in this work is general, and it can help shed further light on the mechanistic aspects of antibody function.

Indexed as

Antibodies, Monoclonal, HumanizedComplementarity Determining RegionsHumansImmunoglobulin GMolecular Dynamics SimulationProgrammed Cell Death 1 ReceptorProtein ConformationAntibodies, Monoclonal, HumanizedComplementarity Determining RegionsImmunoglobulin GpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID34853348
PMCPMC8636491
OpenAlexW3217206183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.